Janus kinase 2 (JAK2)V617F-activating mutations (JAK2mu) occur in myeloproliferative disorders (MPDs) and myelodysplastic syndromes (MDSs). Cell lines MB-02, MUTZ-8, SET-2 and UKE-1 carry JAK2V617F and derive from patients with MPD/ MDS histories. Challenging the consensus that expression of JAK2V617F is the sole precondition for cytokine independence in class I cytokine receptor-positive cells, two of four of the JAK2mu cell lines were growth factor-dependent. These cell lines resembled JAK2wt cells regarding JAK2/STAT5 activation: cytokine deprivation effected dephosphorylation, whereas erythropoetin or granulocyte colony-stimulating factor induced phosphorylation of JAK2 and STAT5. Cytokine independence correlated with low expression and cytokine dependence with high expression of the JAK/STAT pathway inhibitor suppressor of cytokine signaling 2 (SOCS2) suggesting a two-step mechanism for cytokine independence of MPD cells: (i) activation of the oncogene JAK2V617F and (ii) inactivation of the tumor suppressor gene SOCS2. Confirming that SOCS2 operates as a negative JAK2V617F regulator, SOCS2 knockdown induced constitutive STAT5 phosphorylation in JAK2mu cells. CpG island hypermethylation is reported to promote SOCS gene silencing in malignant diseases. Accordingly, in one of two cytokine-independent cell lines and in two of seven MPD patients, we found SOCS2 hypermethylation associated with reduced promoter access to transcription factors. Our results provide solid evidence that SOCS2 epigenetic downregulation might be an important second step in the genesis of cytokineindependent MPD clones.
Introduction
Expression of suppressor of cytokine signaling (SOCS) genes is induced by various cytokines. SOCS proteins, in turn, act in a negative feedback loop as regulators of cytokine-triggered cell signaling. [1] [2] [3] Aberrant methylation of SOCS genes, correlated with transcriptional silencing, has been described in solid tumors and hematopoetic diseases. [4] [5] [6] [7] [8] [9] [10] Silencing of SOCS genes may lead to both cytokine hypersensitivity and independency, thereby contributing to tumorigenesis. 4 ,10 SOCS gene hypermethylation and deletion has also been described in cases of myeloproliferative disorders (MPDs), carrying the Janus kinase 2 (JAK2)V617F point mutation. 10, 11 JAK2V617F is frequently found in BCR/ABL1-negative MPD and in rare cases of myelodysplastic syndromes (MDSs). In the presence of type I cytokine receptors, the JAK2V617F protein induces cytokineindependent activation of the JAK2/STAT5 pathway. 12, 13 Recently, we described four JAK2V617F mutant (JAK2mu) acute myeloid leukemia-derived cell lines from patients with histories of MPD or MDS. 14 In apparent conflict with the view of JAK2V617F as an activating mutation that should lead to cytokine independency, two of the four cell lines were cytokine-dependent. We provide cogent evidence that SOCS2 is an antagonist of not only wild-type JAK2 (JAK2wt), but also of JAK2V617F, and that epigenetic regulation of SOCS2 gene expression may be an important second step in cytokineindependent cell growth.
Materials and methods

Human cell lines
Cell lines SET-2 (ACC 608) and UT-7 (ACC 137) are supplied by the DSMZ (German Collection of Microorganisms and Cell Cultures) cell bank. Cell lines MB-02, 15 MUTZ-8, 16 SKNO-1 17 and UKE-1 18 were generously provided by the original investigators. The cell lines were cultivated according to the protocols described earlier. 19 
Human tissue samples
After informed consent was given, five bone marrow and two peripheral blood specimens were obtained during routine clinical assessment of seven adult patients with MPD in chronic phase. The collection of patient samples for analysis of genetic and epigenetic changes was approved by the local ethics committee. DNA extraction was performed from unselected cells from bone marrow or peripheral blood. 10 
Cytokines and inhibitors
Erythropoetin, granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor were purchased from R&D Systems (Wiesbaden, Germany) and interleukin-3 from Strathmann Biotec (Hamburg, Germany). JAK inhibitor I was purchased from Calbiochem/Merck Biosciences (Schwalbach, Germany).
[ 3 H]-thymidine uptake and detection of apoptotic cells
Assays of [
3 H]-thymidine incorporation were performed as follows: 2.5 Â 10 4. cells (in 100 ml) were seeded in triplicate in 96-well flat-bottom microtiter plates. Cytokines were added as 2 Â concentrated solution in 100 ml volumes. For the last 3 h of the 48-h incubation period, 1 mCi [ 3 H]-thymidine (Amersham Pharmacia Biotech, Freiburg, Germany) was added to each well.
Immunoprecipitation and western blot analysis
Analysis of STAT5 and JAK2 phosphorylation was performed as described earlier. 20 For cytokine starvation, cells were washed twice and kept overnight in medium containing 0.4% bovine serum albumin instead of fetal bovine serum. Rabbit anti-JAK2 antiserum, used for immunoprecipitation and western blot analysis, and mouse anti-phosphotyrosine antibody 4G10 were obtained from Upstate/Biomol (Hamburg, Germany). Rabbit anti-STAT5B antiserum for immunoprecipitation was purchased from R&D Systems. Mouse anti-STAT5A/B antibody for western blot analysis was purchased from Dianova (Hamburg, Germany). Samples were subjected to SDS electrophoresis on 8% polyacrylamide gels. Specific bands on nitrocellulose membranes were visualized with the biotin/streptavidin-horseradish peroxidase system (Amersham, Freiburg, Germany) in combination with the 'Renaissance western Blot Chemoluminescence Reagent' protocol (DuPont, Bad Homburg, Germany).
DNA microarray hybridization and analysis
Quality and integrity of the total RNA isolated was controlled by running all samples on an Agilent Technologies 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany). For biotin-labeled target synthesis starting from 3 mg of total RNA, reactions were performed using standard protocols supplied by the manufacturer (Affymetrix, Santa Clara, CA, USA). The concentration of biotin-labeled cRNA was determined by ultraviolet absorbance. In all cases, 12.5 mg of each biotinylated cRNA preparation were fragmented and placed in a hybridization cocktail containing four biotinylated hybridization controls (BioB, BioC, BioD and Cre) as recommended by the manufacturer. Samples were hybridized to an identical lot of Affymetrix GeneChip HG_U133 Plus 2.0 for 16 h. After hybridization, the GeneChips were washed, stained with streptavidin-phycoerythirin and read using an Affymetrix GeneChip fluidic station FS-400 and scanner GCS3000. Analysis of microarray data was performed using the Affymetrix GCOS 1.4 software. For normalization, all array experiments were scaled to a target intensity of 150, otherwise using the default values of GCOS 1.2.
Real-time PCR analysis
Quantitative PCR was performed on a 7500 Applied Biosystems real-time PCR system using the manufacturer's protocol (Darmstadt, Germany). For mRNA quantification, reverse transcription was performed using the SuperScript II reverse transcriptase kit (Invitrogen, Karlsruhe, Germany). TaqMan probes (Applied Biosystems) were used to quantify JAK2 and SOCS2 expression levels with TATA-box-binding protein (TBP) as endogenous control. SOCS2 gene amplification was determined using the following primers in a SYBR green assay system (Applied Biosystems) with c-MYC as internal control and CTNNA1 as deletion control: SOCS2 intron 2 forward:
Cytogenetic analysis
Karyotypic analysis and fluorescence in situ hybridization were performed as described earlier. 21 Tilepath bacterial artificial chromosome clones were sourced from BAC-PAC Resources (Children's Hospital, Oakland, CA, USA) and chromosome painting probes from Cambio (Cambridge, UK). The D12Z3 chromosome 12 centromere probe (pA12H8) was kindly supplied by Dr LHJ Looijenga. Probe preparation and labeling were as described earlier. 21 Imaging and analysis were performed using an Axioscope 2 fluorescence microscope system (Zeiss, Goettingen, Germany) and CytoVision FISH software (Applied Imaging, Newcastle, UK).
SOCS2 methylation analysis
Methylation of SOCS2 5 0 -CpG-rich areas was assessed by (i) bisulfide conversion plus sequencing using primers described earlier 4 and (ii) by digestion with the methylation-sensitive restriction enzyme HhaI and the SYBR green-based real-time PCR system. (i) About 1 mg DNA of cell lines and patient samples (seven MPD patients) were bisulfide-converted according to the protocol of the supplier (Active Motif, Rixensart, Belgium). Products of SOCS2-specific PCR 4 were cloned into the pGEM-T easy vector system (Promega, Mannheim, Germany), a minimum of five clones were sequenced for each PCR product.
(ii) DNA (400 ng) was digested for 30 min (37 1C) with restriction enzyme HhaI (Fermentas, St Leon-Rot, Germany), purified with a commercial kit (Qiagen, Hilden, Germany) and subjected to PCR analysis. Sequence bounded by primer pair A lacked HhaI sites and was used as endogenous control. Sequence amplified by primer pair B contained one HhaI site. PCR products of undigested DNA of each individual cell line were used as calibrator samples. DNA treated with HhaI methyltransferase was used as positive control. SOCS2 A forward:
Lentiviral constructs
To generate the lentiviral plasmid S-SOCS2-IEW, MIG-SOCS2 kindly provided by J Melo (Imperial College London, Hammersmith Hospital, London, UK) was digested with EcoRI and the resulting DNA fragment (B800 nt) was blunt end-ligated into the BamII site of the lentiviral plasmid SIEW (S ¼ SFFV,
Construction of SOCS2 shRNA expression cassettes
Two DNA oligonucleotides corresponding to positions 752-771 and 770-789 of the human SOCS2 gene sequence (GeneBank accession no. AF037989) were subjected to BLAST homology search and thereafter chemically synthesized including 5 0 -BglII and a 3 0 -SalI restriction site cloning overhangs (BioSpring, Frankfurt, Germany). The numbering of the first nucleotide of the shRNAs refers to the ATG start codon. The oligonucleotide sequences of the most effective shRNAs used in this study were as follows: FP752SOCS2:
0 . The non-complementary 9-nt loop sequences are underlined, and each sense oligonucleotide harbors a poly-T stretch as polIII transcription termination signal. The oligonucleotides were SOCS2 in JAK2V617F mutant cells H Quentmeier et al annealed and inserted 3 0 of the H1-RNA promoter into the BglII/ SalI-digested pBlueScript-derived pH1 plasmid to generate pH1-SOCS2-752 and pH1-SOCS2-770 as described earlier. 22 The isolated clones were verified by DNA sequencing. The plasmid pH1-GL4 (control) has been described earlier. 22 
Construction of lentiviral vectors
pdc-SR were used to generate lentiviral transgenic plasmids containing H1-shRNA expression cassettes located in the U3 region of the D3 0 -LTR. 22 . To generate the lentiviral plasmids pdcH1-SOCS2-752-SR and pdcH1-SOCS2-770-SR, the plasmids pH1-SOCS2-752 and pH1-SOCS2-770 were digested with SmaI and HincII, and the resulting DNA fragments (360 nt) were blunt end-ligated into the SnaBI site of the pdc-SR. The lentiviral plasmids encode RFP EXPRESS as reporter gene.
Preparation of recombinant lentiviral supernatants and lentiviral transduction
VSV.G-pseudotyped lentiviral particles were generated by calcium phosphate cotransfection of 293T cells. Viral supernatants were concentrated by low-speed centrifugation. dcH1-shRNA-SR lentiviral preparations were titrated in triplicate by serial dilutions of the concentrated vector stocks on 1 Â 10 5 K-562 cells in 24-well plates. The number of RFP-positive cells was analyzed 72 h post-transduction by flow cytometry analysis (FACS-Calibur, Becton-Dickinson, Heidelberg, Germany), and the titers were averaged and typically ranged between 1 and 5 Â 10 8 IU/ml. Lentiviral supernatants were used to transduce MB-02 and UT-7 cells for silencing of SOCS2 with a multiplicity of infection between 2 and 4 as described earlier. 23 Lentiviral supernatants were also used to transduce SET-2 cells for the overexpression of SOCS-2.
Results and discussion
Cell lines with JAK2V617F mutations
The V617F mutation in the JH2 domain of the JAK2 gene disrupts inhibition of the enzyme's catalytic domain, creating a constitutively activated kinase thatFin the presence of dimerized type I cytokine receptorsFallows cytokine-independent cell growth.
12,13 Recently, we described four cell lines with a history of MPD or MDS carrying the JAK2V617F mutation: MB-02, MUTZ-8, SET-2 and UKE-1.
14 Confirming that JAK2V617F acts as an oncogene, the JAK2mu cell lines displayed higher sensitivities to JAK inhibitorsFassessed by growth inhibition and induction of apoptosisFthan JAK2wt cell lines. 14, 24 We show here that the activity of JAK2V617F may be regulated by SOCS molecules. Starting point for this study was the observation that two JAK2mu cell lines (MB-02 and MUTZ-8) were cytokine-dependent although homozygous for the JAK2 mutation.
14 Assessing cell growth, we verified that cell lines MB-02 and MUTZ-8 expressed class I cytokine receptors (Table 1) . Both cell lines expressed the JAK2mu protein, but behaved like JAK2wt cell lines, as cytokines significantly increased JAK2 and STAT5 phosphorylation (Figure 1a ; Supplementary Figure 1) . Constitutive JAK2 and STAT5 phosphorylation levels were higher in the cytokine-independent cell lines SET-2 and UKE-1 than in the dependent cell lines, and reducible by JAK inhibitors at concentrations that led to the inhibition of cell growth and to the induction of apoptosis (Figure 1b; Supplementary Figure 1) .
SOCS2: high expression in cytokine-dependent cell lines
Gene expression profiling of the four MPD/MDS-derived JAK2mu cell lines showed that SOCS2 was one of the genes most differentially expressed between cytokine-dependent and cytokine-independent cell lines (data not shown). Quantitative ]-thymidine incorporation, 48 h after onset of stimulation with cytokines (Epo 10 U/ml; G-CSF 10 ng/ml; IGF-I 100 ng/ml and TPO 10 ng/ml). 
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SOCS2: a negative regulator for JAK2V617F
SOCS proteins are negative regulators of the JAK/STAT pathway.
1-3 SOCS1 and SOCS3 inhibit the JAK/STAT pathway by direct interaction with JAK proteins, whereas SOCS2 presumably binds to cytokine receptors. 25 In polycythemia vera, low-level expression of SOCS2 in insulin-like growth factor-I-treated BFU-E colonies contributes to IGF-I hypersensitivity and to erythroid overgrowth. 26 These observations suggest that the oncogenic effect of the JAK2V617F mutation may be amplified by downregulation of SOCS2. The exact mode of action underlying SOCS2 inhibition of JAK2V617F signaling remains elusive. SOCS2 is not only reported to inhibit contact between class I cytokine receptors and JAK2, 25 but is also reported to accelerate proteasome-dependent turnover of SOCS3. 27 In the latter scenario, expression of SOCS2 would lead to silencing of JAK2V617F through its SOCS3-degrading effect. SOCS3, a well-known inhibitor of wild-type JAK2, potentiates the activity of JAK2V617F. 28 Thus a priori, one would expect that enforced downregulation of SOCS2 would lead to higher constitutive activation of the JAK2/STAT5 pathway in JAK2mu cells. To test this, we suppressed SOCS2 in cytokine-dependent JAK2mu cells by RNAi. Downregulation of SOCS2 led to an increase of STAT5 phosphorylation in cytokinestarved MB-02 cells, confirming that SOCS2 acts as an antagonist of JAK2V617F and that regulation of SOCS2 expression may be of importance for cell signaling in JAK2mu MPD cells (Figure 3) . Consequently, the overexpression of SOCS2 inhibited constitutive STAT5 phoshorylation in the cytokine-independent JAK2mu cell line SET-2 ( Supplementary  Figure 2) . SOCS2-transfected SET-2 cells did not grow comparably well as untransfected cells or cells transfected with a control plasmid, suggesting that by regulating JAK2mu, SOCS2 had an impact on viability and cell growth.
SOCS2: epigenetic gene silencing
Recently, epigenetic inactivation of SOCS1 has been proposed as a mechanism complementary to the JAK2V617F mutation in the pathogenesis of MPD. 10 . Consistent with such a model is the report of the case of an MPD patient with concurrent JAK2V617F mutation and deletion at 12q22 including SOCS2.
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According to this notion, downregulation of SOCS gene expression, by deletion or gene silencing would be the second step that besides the JAK2V617F mutation leads to the emergence of cytokine-hyperresponsive or cytokineindependent MPD clones. Therefore, we tested whether SOCS2 was deleted or methylated in the cytokine-independent JAK2mu cell lines.
The SOCS2 gene is located on the long arm of chromosome 12 (12q22). Results of fluorescence in situ hybridization analysis with bacterial artificial chromosome clones adjoining the SOCS2 locus excluded deletion of chromosome 12 or parts of chromosome 12 containing SOCS2 (Figure 4 ; shown for cell lines MUTZ-8 and SET-2 only). Furthermore, quantitative genomic PCR confirmed that the low expression of SOCS2 in the cytokine-independent cell lines was not due to a microdeletion of SOCS2 (Figure 2b) .
To test the methylation of SOCS2, we digested the DNA of cytokine-dependent and cytokine-independent JAK2mu cell lines with a methylation-specific restriction enzyme and assessed the extent of methylation by quantitative PCR analysis. Our results confirmed that gene methylation might explain low SOCS2 levels, as cell line UKE-1 (one out of two cytokine- (24 h) from the medium of JAK2wt cell line UT-7 had the same effect on SOCS2 expression as JAK inhibitor I in JAK2mu cell line SET-2. Note the extended half-life of SOCS2 mRNA when compared to mRNAs of other SOCS family members. 25 Epo, erythropoetin; GM-CSF, granulocytemacrophage colony-stimulating factor; IL-3, interleukin-3. SOCS2 in JAK2V617F mutant cells H Quentmeier et al pathway and the expression of SOCS2 (Figure 1b, 6b) . In contrast, JAK inhibition failed to cause downregulation of SOCS2 in cell line UKE-1 (Figure 6b ). According to the widely held view, promoter methylation impedes binding of transcription factors to their DNA-binding sites. 30 Thus, the results of SOCS2 expression support the data of the direct methylation analyses: of the four JAK2mu cell lines, only the cytokineindependent cell line UKE-1 carries a methylated SOCS2 promoter. Our results do not explain why the second cytokine-independent cell line (SET-2) expresses low levels of SOCS2, but confirm that DNA methylation is a plausible cause for low expression levels of SOCS2, and may thus contribute to cytokine independence of the affected cells.
Hypermethylation of SOCS2 in MPD patients
To find out whether SOCS2 hypermethylation occurs in primary MPD cells, we performed bisulfide conversion of DNA from seven MPD patients, from which SOCS2-specific PCR products were cloned and sequenced. Not knowing the exact percentages of healthy bystander cells in the samples, we expected unmethylated clones, plus a few highly methylated clones as indicators of SOCS2 silencing in primary MPD cells. Accordingly, we found SOCS2 hypermethylation in two of seven MPD patients (470% CpGs methylated in 2/5 and 1/6 clones, respectively; Table 2 ). JAK2mu-specific PCR, performed as described previously, 10 showed that four of the seven patients carried the JAK2V617F mutation, one of them displaying SOCS2 hypermethylation (Table 2 ). High-throughput techniques like pyrosequencing will be necessary to reassess the correlation between occurrence of the JAK2V617F mutation and hypermethylation of SOCS2 in a larger cohort of MPD patients. Our data provide first evidence that both events may occur in the same cell andFas described for cell linesFinduce cytokine independence.
Conclusion
We present cogent evidence that SOCS2 is an antagonist not only of wild-type JAK2 but also of JAK2V617F. Methylation of SOCS2 associated with low-level expression of SOCS2 in one out of two MPD-derived cell lines was also found in two of seven MPD patient samples. We conclude that downregulation of SOCS2 gene expression might be an important second step for the rise of cytokine-independent MPD clones. DNA from MPD patients was bisulfide-converted, the SOCS2 CpGrich area amplified as described 4 and PCR products were cloned. At least five clones were sequenced for each sample. The full-length PCR product contained 34 CpG sites. JAK2 mutational status was assessed by PCR.
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